en · de · es · fr · pt
cjc-1295-notes.peptides6608.com › Wiki › Structure And Receptor Pharmacology — Research Overview

Structure And Receptor Pharmacology — Research Overview

By Editorial Desk · published 2025-08-04 · last reviewed 2025-09-20 · Wiki

A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2025-09-20. Anything still debated is marked as such rather than presented as settled.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Receptor Action and Pharmacokinetics

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.

Cjc-1295 at a glance

PropertyValueNotes
Peptide classSynthetic GHRH analogueBuilt on a 29 residue sequence
Primary targetGHRH receptor (GHRHR)Class B G protein coupled receptor
Unconjugated half lifeMinutesLimited by protease degradation
Key modificationFour residue substitutionsPositions 2, 8, 15 and 27
Common synonymModified GRF(1-29)Usually denotes the form without DAC

CJC-1295 Structure And Mechanism

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

Related pages on this site

Molecular Background and Naming

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

Background from the literature

=== Full table === The nuclide table below shows nuclides (often loosely called "isotopes", but this term properly refers to nuclides with the same atomic number, see above), including all with half-life of at least one day. They are arranged with increasing atomic numbers from left to right and increasing neutron numbers from top to bottom. Cell color denotes the half-life of each nuclide; if a border is present, its color indicates the half-life of the most stable nuclear isomer. In graphical browsers, each nuclide also has a tool tip indicating its half-life. Each color represents a certain range of length of half-life, and the color of the border indicates the half-life of its nuclear isomer state. Some nuclides have multiple nuclear isomers, and this table notes the one with the longest half-life. Dotted borders mean that a nuclide has a nuclear isomer with a half-life in the same range as the ground state nuclide. The dashed lines between several nuclides of the first few elements are the experimentally determined proton and neutron drip lines.

==== Post-mastectomy fat-graft reconstruction ==== The reconstruction of the breast(s) with grafts of autologous fat is a non-implant alternative to further surgery after a breast cancer surgery, be it a lumpectomy or a breast removal – simple (total) mastectomy, radical mastectomy, modified radical mastectomy, skin-sparing mastectomy, and subcutaneous (nipple sparing) mastectomy. The breast is reconstructed by first applying external tissue expansion to the recipient-site tissues (adipose, glandular) to create a breast-tissue matrix that can be injected with autologous fat grafts (adipocyte tissue); the reconstructed breast has a natural form, look, and feel, and is generally sensate throughout and in the nipple-areola complex (NAC). The reconstruction of breasts with fat grafts requires a three-month treatment period – begun after 3–5 weeks of external vacuum expansion of the recipient-site tissues. The autologous breast-filler fat is harvested by liposuction from the patient's body (buttocks, thighs, abdomen), is refined and then is injected (grafted) to the breast-tissue matrices (recipient sites), where the fat will thrive. One method of non-implant breast reconstruction is initiated at the concluding steps of the breast cancer surgery, wherein the oncological surgeon is joined by the reconstructive plastic surgeon, who immediately begins harvesting, refining, and seeding (injecting) fat grafts to the post-mastectomy recipient site.

=== Stroke prevention === Transcranial Doppler ultrasound (TCD) can detect children with sickle cell who have a high risk for stroke. The ultrasound test detects partially obstructed blood vessels by measuring blood flow into the brain, as blood flow velocity is inversely related to arterial diameter. Consequently, high blood flow velocity correlates with narrowed arteries. In children, preventive RBC transfusion therapy has been shown to reduce the risk of first stroke or silent stroke when transcranial Doppler ultrasonography shows abnormal cerebral blood flow. In those who have sustained a prior stroke event, it also reduces the risk of recurrent stroke and additional silent strokes.

== External links == Leptin: Your brain, appetite and obesity by the British Society of Neuroendocrinology Leptin by Colorado State University – last updated 1998 Leptin at 3Dchem.com, description and structure diagrams Overview of all the structural information available in the PDB for UniProt: P41159 (Leptin) at the PDBe-KB.

Sources: en.wikipedia.org

Reference notes

In the brain, the canonical mechanism of CB1 receptor activation is a form of short-term synaptic plasticity initiated via retrograde signaling of endogenous CB1 agonists such as 2AG or AEA (two primary endocannabinoids). This mechanism of action is called depolarization-induced suppression of inhibition (DSI) or depolarization-induced suppression of excitation (DSE), depending on the classification of the presynaptic neuron acted upon by the retrograde messenger (see diagram at left). In the case of CB1R agonism on the presynaptic membrane of a GABAergic interneuron, activation leads to a net effect of increased activity, while the same activity on a glutamatergic neuron leads to the opposite net effect. The release of other neurotransmitters is also modulated in this way, particularly dopamine, dynorphin, oxytocin, and vasopressin.

Fibroblast growth factor 19 is a protein that in humans is encoded by the FGF19 gene. It functions as a hormone, regulating bile acid synthesis, with effects on glucose and lipid metabolism. Reduced synthesis, and blood levels, may be a factor in chronic bile acid diarrhea and in certain metabolic disorders.

=== Gastrointestinal health === AM function can be compared to another peptide called pro-adrenomedullin N-terminal 20 peptide (PAMP), which both originate from a common precursor leading to angiogenesis, vasodilation, and anti-inflammatory processes. These two peptides are expressed in the gastrointestinal (GI) tract at a mass level, serving as GI hormones controlling processes like insulin secretion and gastric emptying. Past studies reveal that AM and PAMP also impact gut microbiome composition by fostering the development of beneficial bacteria (i.e., Bifidobacterium and Lactobacillus) and diminishing detrimental microbes.

Anterior pituitary In the hypothalamic–adenohypophyseal axis, releasing hormones, also known as hypophysiotropic or hypothalamic hormones, are released from the median eminence, a prolongation of the hypothalamus, into the hypophyseal portal system, which carries them to the anterior pituitary where they exert their regulatory functions on the secretion of adenohypophyseal hormones. These hypophysiotropic hormones are stimulated by parvocellular neurosecretory cells located in the periventricular area of the hypothalamus. After their release into the capillaries of the third ventricle, the hypophysiotropic hormones travel through what is known as the hypothalamo-pituitary portal circulation. Once they reach their destination in the anterior pituitary, these hormones bind to specific receptors located on the surface of pituitary cells. Depending on which cells are activated through this binding, the pituitary will either begin secreting or stop secreting hormones into the rest of the bloodstream.

== External links == Official website Example SWAPO Party Youth League web page. "Latest from the SPYL Frontlines". spyl.swapo.party. SWAPO Party Youth League. 28 August 2012. Archived from the original on 28 August 2012. Retrieved 7 November 2024.

Sources: en.wikipedia.org

Reference notes

=== Transport Reaction === The generalized transport reaction catalyzed by members of the CPA2 family is:M+ (in) + nH+ (out) ⇌ M+ (out) + nH+ (in).(The carrier-mediated mode)Some members may also catalyze:M+ (in) ⇌ M+ (out).(The channel-mediated mode)

Detect varying protein concentrations in a complex sample Track an ever-changing HCP population and their concentrations during a manufacturing process Analyse many proteins at once Measure low abundant HCPs overshadowed by the high abundant target protein product Characterize HCP-ELISA reagents, including both the antibodies and the associated kit standard Recently, the MS method has been further improved through the method SWATH LC-MS. SWATH is a data independent acquisition (DIA) form of mass spectrometry, where the mass range is partitioned in small mass windows, which is then analysed with tandem MS (MS/MS). The key advantages are the reproducibility for both individual HCP identification and absolute quantification by applying internal protein standards. Despite the solid improvements of this method of protein analysis, there are also limitations, the main of which is that it requires a high level of expertise and advanced instrumentation to conduct the analysis.

After a dispute with Yale over his forced retirement and the rights to his invention of electrospray ionization, Fenn moved to Richmond, Virginia to join Virginia Commonwealth University's (VCU) department of chemistry as an analytical chemistry professor. VCU established an engineering department in the late 1990s, and Fenn held a joint professorship between the two departments until his death. Even in his 80s, Fenn enjoyed the opportunity to be in the lab doing research, saying, "I like to mingle and exchange with the young people. It gets me out from underfoot at home."

=== 2017–2021: Rainier Fog === In January 2017, Mike Inez stated in an interview that the band had begun work on a new album. In June 2017, it was reported that the band would return to Studio X (formerly Bad Animals Studios) in Seattle to record a new album later that month, for a tentative early 2018 release. The sessions were helmed by Nick Raskulinecz, who produced the band's last two albums. Studio X was the studio where Alice in Chains recorded its 1995 self-titled album. According to Inez, the band was not signed to a label, having completed its previous two-record contract with the Universal Music Group. "This [upcoming album], we're not sure where it's gonna land ... I mean, we financed ['Black Gives Way To Blue'] on our own too, so we're not too worried about that stuff. We've just gotta get it out to ... a significant label [with worldwide distribution]." The band started recording their sixth studio album on June 12, 2017. On January 11, 2018, producer Nick Raskulinecz announced via Instagram that the album was nearly finished and that there was only one more day left of recording. During an interview with Guitar World published on April 11, 2018, Jerry Cantrell said that the album was recorded at four studios. After recording at Studio X in Seattle, the band went to Nashville to record vocals and lead guitars at Nick Raskulinecz's home studio. But Cantrell had to take an unexpected break from work for a couple of weeks after getting sick on a trip to Cabo for Sammy Hagar's birthday.

Sources: en.wikipedia.org

Frequently asked questions

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

What does the acronym DAC refer to?

DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.

Does this peptide occur naturally in the body?

No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.

How does CJC-1295 raise growth hormone levels?

It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.

Network